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Copyright © 2008 JCBN Summary 15-deoxy-∆12,14-prostaglandin J2 (15d-PGJ2) and an anti-diabetic thiazolidinedione,
troglitazone (TRO) are peroxisome proliferator-activated receptor (PPAR)-γ ligands, which
regulate immuno-inflammatory reactions as well as adipocyte differentiation. We previously
reported that 15d-PGJ2 can suppress interleukin (IL)-1β-induced prostaglandin E2 (PGE2)
synthesis in synoviocytes of rheumatoid arthritis (RA). IL-1 also stimulates PGE2 synthesis in
osteoblasts by regulation of cyclooxygenase (COX)-2 and regulates osteoclastic bone resorption
in various diseases such as RA and osteoporosis. In this study, we investigated the feedback
mechanism of the arachidonate cascade in mouse osteoblastic cells, MC3T3-E1 cells, which
differentiate into mature osteoblasts. Treatment with 15d-PGJ2 led to a significant increase in
IL-1α-induced COX-2 expression and PGE2 production in a dose dependent manner. The
effect of 15d-PGJ2 was stronger than that of TRO. However, it did not affect the expression
of COX-1. In addition, cell viability of MC3T3-E1 cells was not changed in the condition
we established. This means that 15d-PGJ2 exerts a positive feedback regulation of the
arachidonate cascade of PGE2 in osteoblastic cells. These results may provide important
information about the pathogenesis and treatment of bone resorption in a variety of diseases
such as RA and osteoporosis.
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Introduction
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear receptor superfamily of ligand
activated transcriptional factors that include receptors for
steroids, thyroid hormone, vitamin D and retinoic acid [1].
Recently three PPAR subtypes, PPAR-α, PPAR-∆, and
PPAR-γ, were identified and their functions have been
elucidated [2]. PPAR-α is highly expressed in many tissues
exhibiting high carbolic rates of fatty acids [3, 4]. PPAR-γ is
expressed ubiquitously. PPAR-γ is expressed at high levels
in adipose tissue and in parts of the immune system such as
the spleen, monocytes, bonemarrow precursors and helper
T-cell clones [5, 6]. PPAR-γ relates to many diseases such as
inflammation, metabolic diseases (diabetes mellitus and
obesity), arteriosclerosis and malignant tumors. PPAR-γ
plays a central role in the process of adipocyte differentia-15d-PGJ2 Controls the Arachidonate Cascade in MC3T3-E1 Cells
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tion. This receptor and its heterodimeric partner retinoid X
receptor (RXR)-α form a DNA-binding complex that
regulates transcription of adipocyte-specific genes [7,  8].
Heterozygous PPAR-γ deficient mice show overexpression
and hypersecretion of leptin despite a smaller size of adipo-
cytes and decreased fat mass [2, 9].
PPAR-γ is activated by a range of synthetic and naturally
occurring substances, including anti-diabeticthiazo-
lidinediones such as troglitazone (TRO), polyunsaturated
fatty acids, prostaglandin D2 (PGD2) metabolites,
components of oxidized low-density lipoprotein (LDL) and
12/15-lipoxygenase products [10,  11]. We previously
demonstrated that immunoreactive PPAR-γ is expressed in
macrophages and synoviocytes of rheumatoid arthritis (RA)
and its ligands inhibit the growth of synoviocytes in vitro
through apoptosis [12,  13]. Furthermore, 15-deoxy-∆12,14-
prostaglandin J2 (15d-PGJ2), which is a PGD2 metabolite,
had 100-fold higher potency in suppressing the chronic
inflammation and bone destruction of adjuvant-induced
arthritis (AIA) in rats, compared with TRO [12]. The
suppression of bone destruction in AIA is due to the inhibi-
tion of pannus formation, which is thought to be critical for
the development of erosive disease and results in irreversible
destruction of the cartilage and bone in affected joints. We
also previously indicated that 15d-PGJ2 suppresses inter-
leukin (IL)-1β-induced prostaglandin E2 (PGE2) synthesis in
RA synoviocytes through the inhibition of cytosolic phos-
pholipase A2 as well as cyclooxygenase (COX)-2 expres-
sion, which are synthetic enzymes for PG. TRO and other
prostanoids have no inhibitory effects on PGE2 synthesis
[13]. 15d-PGJ2 may act by a different mechanism from that
of TRO in the treatment of RA and negative feedback of the
arachidonate cascade regulation by PG in RA synoviocytes
may be specific for 15d-PGJ2.
IL-1 stimulates PGE2 synthesis in osteoblasts by regula-
tion of COX-2 and regulates osteoclastic bone resorption in
various diseases such as RA and osteoporosis [14, 15]. IL-1,
especially IL-1α, can promote the differentiation of
osteoblast and stimulate the production of various cytokines
in osteoblasts [16, 17]. In addition, the function of PPAR-γ in
bone metabolism has been clarified from experiments using
mesenchymal stem cells, which can differentiate to both
osteoblasts and adipocytes. Some studies suggested that the
expression of PPAR-γ in mesenchymal stem cells promotes
osteoblast differentiation [18]. 15d-PGJ2 is also a direct
inhibitor of IκB kinase independent of PPAR-γ, which
suggests additional anti-inflammatory effects independent
of PPAR-γ [19, 20]. The mechanism of feedback control on
the arachidonate cascade is unclear and dependent on the
type of cells. In this study, we investigated the feedback
mechanism of the arachidonate cascade by 15d-PGJ2 in
mouse osteoblastic cells, MC3T3-E1 cells, which differen-
tiate into mature osteoblasts. Our findings may suggest a
novel therapy for inflammatory diseases including RA, and
clarify the basic mechanism of the bone metabolism of the
mesenchymal osteoblast in inflammatory diseases and
aging.
Materials and Methods
Materials
TRO was obtained from Sankyo Co. Ltd. (Tokyo, Japan)
and 15d-PGJ2 was purchased from Cayman Chemical
(Ann Arbor, MI). IL-1α was from Genzyme Techne
(Minneapolis, MN). Anti-COX-2 antibody and anti-COX-1
antibody were from Santa Cruz Biotechnology Inc (Santa
Cruz, CA). Fetal bovine serum (FBS) and penicillin-
streptomycin mixture were from BioWhittaker (Walkersville,
MD). Phosphate buffered saline (PBS) was obtained from
GIBCO BRL (Grand Island, NY).
Cell culture
The MC3T3-E1 mouse preosteoblast cell line [21] (Riken
Cell Bank, Tsukuba, Japan) was grown in α MEM (Fisher
Scientific, Pittsburgh, PA) containing 10% heat-inactivated
FBS (Bio Whittaker) supplemented with sodium pyruvate
(1 mM), penicillin-streptomycin mixture (100 U/ml) in a
humidified 5% CO2 atmosphere at 37°C. As a pre-
incubation for the treatment of reagents, MC3T3-E1 cells
were cultured for 24 h with α MEM supplemented with 1%
FBS. Then, various concentrations of IL-1α, 15d-PGJ2 and
TRO were added to the cell culture in serum-free α MEM
medium for 6 h. Next, Western blot analysis of COX-1 and
COX-2, PGE2 synthesis assay, and cell viability assay were
performed.
Western blot analysis of COX-1 and COX-2
IL-1α, 15d-PGJ2 and TRO were added to MC3T3-E1
cells at concentrations of 5 ng/ml, 0.1, 1 or 10 µM and 0.1, 1
or 10 µM, respectively, in serum-free α MEM medium for
6 h. After incubation, Western blot analysis was performed
to determine COX-1 and COX-2 protein expression as
described previously [22]. Thirty micrograms of each total
protein extract from MC3T3-E1 cells was analyzed on blots
incubated for 1 h at room temperature with 1:200 dilution of
goat anti-COX-2 antibody (Santa Cruz), and washed,
followed by incubation for 1 h at room temperature with
horseradish peroxidase-linked rabbit anti-goat IgG (1:1500
dilution; EY Laboratories Inc., San Mateo, CA). After being
washed again, blots were analyzed using an Amersham
enhanced-chemiluminescence (ECL) system (Amersham
Pharmacia Biotech, Buckinghamshire, United Kingdom),
and exposed to Hyperfilm (Amersham Pharmacia Biotech)
for 30 s to 5 min, resulting in adequate exposure to visualize
the bands.H. Ishino et al.
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PGE2 synthesis assay
MC3T3-E1 cells were seeded in 24-well tissue culture
plates at a density of 3 × 104 cells/well. 15d-PGJ2 and TRO
were added to duplicate wells at concentrations of 0.1, 1 or
10 µM and 10 µM, respectively, with 5 ng/ml of IL-1α in a
total volume of 500 µl serum-free α MEM medium for 6 h.
The cells were washed three times with PBS, and then
incubated in α MEM medium for a further 1 h period. After
incubation, the conditioned media from the wells were
collected to measure the PGE2 concentration immediately.
The concentration of PGE2 was measured with the PGE2
monoclonal enzyme immunoassay (EIA) kit (assay designs,
Inc. Ann Arbor MI) according to the manufacturer’s instruc-
tions.
Cell viability assay
To evaluate the effect of 15d-PGJ2 on cell growth, MTT
assay was performed. MC3T3-E1 cells were seeded in 96-
well tissue culture plates at a density of 5.0 × 103 cells/well.
MC3T3-E1 cells in duplicated wells were treated with 1 or
5 µM of IL-1α, 10 µM of TRO with 5 ng/ml of IL-1α, and
1, 5, or 10 µM of 15d-PGJ2 with 5 µM of IL-1α, in a total
volume of 200 µl serum-free α MEM medium for 24 h. Cell
viability was measured colorimetrically using the Cell
Counting Kit (Dojindo Chemical, Kumamoto, Japan) and a
microplate reader (Model 550, Bio-Rad Labs., Hercules,
CA) at the test wavelength of 450 nm and the reference
wavelength of 650 nm. This assay is based on cleavage of
the 2-(2-methoxy-4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium, monosodium salt by mito-
chondrial dehydrogenase in viable cells.
Statistical analysis
The number of experiments analyzed is indicated in the
corresponding figure legend. Statistical differences between
the mean values (presented with SD) were determined by
one-way analysis of variance followed by the Student’s t test.
Results
15d-PGJ2 increased expression of COX-2 in MC3T3-E1
cells
15d-PGJ2 suppresses IL-1β-induced PGE2 synthesis in
RA synoviocytes. IL-1 stimulates PGE2 synthesis in osteo-
blasts by regulation of COX-2 and regulates osteoclastic
bone resorption in various diseases such as RA and osteo-
porosis. To investigate the effect of 15d-PGJ2 on IL-1α-
induced COX expression in MC3T3-E1 cells, we used
Western blot analysis. COX-1 protein expression was
identical under any treatment. COX-2 protein was expressed
in IL-1α (5 ng/m)-stimulated cells. Treatment with 0.1–
10 µM of 15d-PGJ2 led to a significant increase of IL-1α-
induced COX-2 protein in a dose dependent manner. 10 µM
of TRO also increased IL-1α-induced COX-2 protein, to
less than that of 10 µM of 15d-PGJ2 (Fig. 1). These data
suggest that 15d-PGJ2 can increase the expression of COX-2
in MC3T3-E1 cells and that this effect of 15d-PGJ2 was
stronger than that of the PPAR-γ ligand, TRO.
15d-PGJ2 increased PGE2 synthesis in MC3T3-E1 cells
Next we analyzed PGE2 synthesis mediated by 15d-PGJ2
or TRO, in IL-1α (5 ng/ml) - stimulated MC3T3-E1 cells.
Treatment with 15d-PGJ2 led to an increase in IL-1α-
induced PGE2 synthesis in a dose-dependent manner, while
10 µM of TRO weakly affected IL-1α-induced PGE2
synthesis (Fig. 2).
Fig. 1. COX-1 and COX-2 expression in TRO and 15d-PGJ2 treated MC3T3-E1 cells. IL-1α (5 ng/ml)-
stimulated MC3T3-E1 cells were incubated with TRO (0.1–10 µM), and 15d-PGJ2 (0.1–10 µM) for
6 h. COX-1 and COX-2 expression in MC3T3-E1 cells were analyzed by Western blotting as
described in Materials and Methods. Treatment with 10 µM of 15d-PGJ2 increased IL-1α-induced
COX-2 expression more than that with 10 µM of TRO. Three separate experiments were performed.15d-PGJ2 Controls the Arachidonate Cascade in MC3T3-E1 Cells
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Cell viability of MC3T3E-1 cells by PPAR-γ ligands and
IL-1α
To investigate the effect of PPAR-γ ligands and IL-1α on
MC3T3E-1 cells, we analyzed cell viability in vitro by a
modified MTT assay. MC3T3E-1 cells were treated with
IL-1α, TRO plus IL-1α and 15d-PGJ2 plus IL-1α. Cell
counting clearly indicated that neither PPAR-γ ligands nor
IL-1α changed the viability of MC3T3E-1 cells (Fig. 3).
Discussion
We examined the production of PGE2 and the expression
of COX-1 and COX-2 in IL-1α-stimulated MC3T3-E1 cells
in vitro. Cell viability of MC3T3-E1 cells was not changed
in the condition we established. Treatment with 15d-PGJ2
led to a significant increase in IL-1α-induced COX-2
expression and PGE2 production in a dose dependent
manner. In addition, this effect was stronger than that of
TRO. However, it did not affect the expression of COX-1.
These results show that 15d-PGJ2 exerts a positive feedback
regulation on the arachidonate cascade of PGE2 in osteo-
blastic cells.
PGE2 is produced in most internal organs including bone
and exerts various actions [23]. PGE2 in bone tissue is
produced mainly by osteoblasts. COX is classified as
constitutively expressed COX-1 and COX-2, which is
induced by stress such as inflammation. In mouse osteo-
blasts, COX-2 is induced by stimulation of IL-1 or IL-6,
and these cytokines can induce bone resorption [24].
Therefore it is thought that production of PGE2 is related to
inflammatory bone resorption dependent on COX-2. PGE2
acts on osteoblasts and induces a receptor activator of NFκB
ligand (RANKL). Furthermore, PGE2 is also an important
factor for this synovial proliferation, a tumor-like structure
called pannus, invades and erodes the cartilage and the
subchondral bone [25]. On the other hand, bone formation
by PGE2 in vivo has been reported in rat, dog, and man, but
is thought to be weaker compared with its action of bone
resorption. On pre-osteoblastic MC3T3-E1 cells, low-dose
PGE2 inhibited cell proliferation and increased alkaline
phosphatase activity, a marker of osteoblast differentiation.
In contrast, high-dose PGE2 promoted cell proliferation,
and decreased alkaline phosphatase activity [26]. PGE2
tends to be related with bone resorption, but it’s dependent
on various conditions.
We previously reported that IL-1β-increased COX-2
expression on RA synoviocytes, and 15d-PGJ2 inhibited
COX-2 expression in a dose dependent manner by negative
feedback regulation [13]. In addition, this effect of 15d-PGJ2
was stronger than that of TRO, which is also a ligand of
PPAR-γ. In the current study, we administered 15d-PGJ2
and TRO to IL-1α-stimulated MC3T3-E1 cells. Contrary to
our expectation, 15d-PGJ2 and TRO induced more COX-2
expression and PGE2 production on MC3T3-E1 cells. This
effect of 15d-PGJ2 in PGE2 synthesis was stronger than that
of TRO. Moreover, the number of MC3T3-E1 cells was not
changed in this condition, suggesting that COX-2 received
positive feedback from 15d-PGJ2 on MC3T3-E1 cells
Fig. 2. PGE2 synthesis in TRO and 15d-PGJ2 treated MC3T3-
E1cells. MC3T3-E1 cells were incubated with the indi-
cated concentrations of 15d-PGJ2 (0.1–10 µM), TRO
(10 µM), with IL-1α (5 ng/ml) for 6 h, and further incu-
bated in α MEM medium for 1 h. Next, PGE2 concentra-
tions of the supernatants were quantified by enzyme im-
munoassay (EIA). Values are expressed as means ± SD
of three experiments with duplicate samples. *Signifi-
cant difference from control IL-1α (p<0.05). **Signifi-
cant difference from control IL-1α (p<0.01).
Fig. 3. Cell viability of MC3T3-E1 cells by TRO, 15d-PGJ2 and
IL-1α. The viability of MC3T3-E1 cells treated with IL-
1α (1, 5 ng/ml), TRO (10 µM), and 15d-PGJ2 (1, 5,
10 µM) for 6 h was measured with an MTT assay and
expressed as a percentage of the control. PPAR-γ ligands
did not change the viability of MC3T3-E1 cells. Data
represent mean ± SD of three experiments with duplicate
samples.H. Ishino et al.
J. Clin. Biochem. Nutr.
68
(Fig. 4). The finding that the effect on COX-2 production by
15d-PGJ2 was stronger than that by TRO may be due to
other mechanisms independent of PPAR-γ. For example,
15d-PGJ2 binds with SRC-1,-2, and P300 which are co-
activators of PGJ2, whereas TRO is not [27]. In addition,
15d-PGJ2 goes through cell surface receptors unrelated to
PPAR-γ and has an anti-inflammatory effect. On MCF-7
breast cancer cells, 15d-PGJ2 has an anti-inflammatory
effect mediated by inhibition of COX-2 through a cell
membrane receptor restraining IκB kinase, which is not
related to PPAR-γ. Moreover osteoblasts may have different
mechanisms through receptors except PPAR-γ in synovio-
cytes, but they have not yet been fully elucidated.
In this study 15d-PGJ2 and TRO enhanced COX-2 expres-
sion of IL-1α-stimulated MC3T3-E1 cells. IL-1 is a potent
inducer of bone resorption. Induction of PGE2 production
through COX-2 overexpression of osteoblasts might stimu-
late bone resorption, and it was thought to be one of the
various effects of PPAR-γ ligands. In addition, 15d-PGJ2
also suppressed the differentiation of osteoclast in vitro [28].
Bone resorption is greater than bone formation in osteo-
porosis, so bone mineral density is decreased. Thus, 15d-
PGJ2 is an effective treatment reagent for bone resorption in
inflammatory diseases such as RA because of its anti-
inflammatory effects. However the response between COX-
2 and 15d-PGJ2 may be different in other bone resorption
diseases. Our results including the feedback regulation of
the arachidonate cascade in osteoblasts provide important
information about the pathogenesis and treatment of bone
resorption in a variety of diseases.
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